One of the great paradoxes in medicine today is the reality that drug prices are rising at the lowest level in years, yet both patients and employers are feeling more of a squeeze on drug costs than ever before. Ironically, both of these trends — slowing growth, rising pain at the pharmacy counter — have their roots in the same supply chain middleman: pharmacy benefit managers (PBMs).
In National Pharmaceutical Council President Dan Leonard's latest column in Chain Drug Review, he explores the mismatch between the savings PBMs boast about and the pinch patients are feeling in their pockets, as well as the disconnect between the role employers believe their PBMs play in managing prescription drug benefits and employers’ perceptions of the overall value they receive from their PBMs.
>> Read Mr. Leonard's full column in Chain Drug Review